GDTC vs GENB

CytoMed Therapeutics Limited vs Generate Biomedicines, Inc. — Valuation Comparison 2026

GDTC

Pharmaceutical Preparations
CytoMed Therapeutics Limited
Quality
5.1
out of 10
Value Trap
12
SAFE
Price
$1.17
Last close
Models
9/13
Active
VS

GENB

Pharmaceutical Preparations
Generate Biomedicines, Inc.
Quality
1.8
out of 10
Value Trap
Price
$13.12
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType GDTC Fair ValueGDTC Upside GENB Fair ValueGENB Upside
Bayesian DCF Intrinsic $0.35 -70.2% $3.57 -72.8%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.37 -68.0% $5.70 -56.5%
PWERM Option-Based $1.27 +8.5% $8.93 -31.9%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for GDTC vs GENB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GDTC vs GENB — Which Stock Is More Undervalued?

GDTC scores higher with a 5.1/10 quality rating vs GENB's 1.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing CytoMed Therapeutics Limited (GDTC) and Generate Biomedicines, Inc. (GENB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GDTC currently trades at $1.17 with a QOC of 5.1/10, while GENB trades at $13.12 with a QOC of 1.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).